News & Updates

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Product Highlight - Losartan potassium, amlodipine besilate (RiteMED Losartan potassium + Amlodipine besilate)

Film-coated tablet 50 mg/5 mg, 100 mg/5 mg and 100 mg/10 mg

Dapagliflozin Catania SGLT2i

Why Combine? Addressing the Gap for Blood Pressure Control

Sulodexide and its multifaceted role in the multiverse of vascular diseases

[ multiverse_Sulodexide ]

Speakers:

Gilbert C. Vilela, MD, FPCP, FPCC, FACC, FESC, FAsCC
Cardiologist
Examiner, Philippine Specialty Board of Cardiology
Past President, Philippine College of Cardiology
Former Deputy Executive Director for Education, Training and Research, Philippine Heart Center

Rosella S. Arellano, MD, FPCP, FPCC
Cardiologist, Adult Vascular Medicine Specialist
Past President, Philippine Society of Vascular Medicine
Training Officer, Clinical Research Fellowship in Vascular Medicine, Philippine Heart Center

Eugenio B. Reyes, MD, FPCP, FPCC, FACC
Cardiologist
Past Medical Director, Manila Doctors Hospital
Associate Professor, Department of Medicine, University of the Philippines – College of Medicine

Maria Honolina S. Gomez, MD, FPCP, FPCEDM, FACE
Endocrinologist
(Retired) Professor 5, University of Sto. Tomas Faculty of Medicine and Surgery
Past Chair, Philippine Board of Internal Medicine, Philippine College of Physicians

Apixaban (Eliquis): Lowering the Risk of Fatal Ischaemic and Haemorrhagic Events in Anticoagulation

 With robust clinical trial and real-world data showing significant advantages over traditional agents like warfarin, direct oral anticoagulants (DOACs) have transformed anticoagulation therapy. Their efficacy and ease of use have made DOACs like rivaroxaban and apixaban (Eliquis) key therapeutic agents of anticoagulation.^1,2

Apixaban (Eliquis): Superior anticoagulation efficacy with minimized bleeding risks

The coexistence of hypertension and dyslipidemia contributes to an increased risk of CVD, warranting efficient management strategies.

[ Dr Magno leads the first topic on evidence-based management of hypertension ]

Cardiovascular diseases (CVD) are the leading cause of death globally, with hypertension and dyslipidemia as major modifiable risk factors. The coexistence of hypertension and dyslipidemia contributes to an increased risk of CVD, warranting efficient management strategies.¹

On February 27, 2025, at the 30th joint convention of the Philippine Society of Hypertension and Philippine Lipid and Atherosclerosis Society, Servier Philippines hosted a lunch symposium led by Dr Jose Donato Magno and Dr Ma. Cecille Cruz. They presented current evidence and evolving approaches in managing clinical scenarios in patients with both hypertension and dyslipidemia.

Eliquis transforms anticoagulation approaches in stroke and systemic embolism

Product Highlight - Dapagliflozin (Glifixy)

Film-coated tablet 10 mg